Walleye Capital LLC Has $304,000 Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Walleye Capital LLC decreased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 75.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,073 shares of the biopharmaceutical company's stock after selling 172,400 shares during the period. Walleye Capital LLC owned 0.09% of Sage Therapeutics worth $304,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Picton Mahoney Asset Management boosted its position in Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Sage Therapeutics during the fourth quarter valued at about $49,000. Ieq Capital LLC acquired a new position in Sage Therapeutics during the 4th quarter worth $57,000. US Bancorp DE increased its stake in Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 2,446 shares during the period. 99.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SAGE has been the topic of several analyst reports. HC Wainwright restated a "neutral" rating and issued a $12.00 target price (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Canaccord Genuity Group reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a report on Friday. Bank of America initiated coverage on Sage Therapeutics in a report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target on the stock. Finally, Piper Sandler reduced their price objective on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, January 2nd. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Price Performance

NASDAQ:SAGE remained flat at $7.79 during trading hours on Friday. The company's stock had a trading volume of 1,020,475 shares, compared to its average volume of 1,219,777. The business has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $6.75. Sage Therapeutics, Inc. has a 52-week low of $4.62 and a 52-week high of $14.71. The firm has a market cap of $478.94 million, a price-to-earnings ratio of -1.18 and a beta of 0.48.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, equities research analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.